AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2021.
作者信息
Thill Marc, Friedrich Michael, Kolberg-Liedtke Cornelia, Albert Ute-Susann, Banys-Paluchowski Maggie, Bauerfeind Ingo, Blohmer Jens-Uwe, Budach Wilfried, Dall Peter, Fallenberg Eva M, Fasching Peter A, Fehm Tanja, Gerber Bernd, Gluz Oleg, Harbeck Nadia, Heil Jörg, Huober Jens, Jackisch Christian, Kreipe Hans-Heinrich, Krug David, Kühn Thorsten, Kümmel Sherko, Loibl Sibylle, Lüftner Diana, Lux Michael P, Maass Nicolai, Mundhenke Christoph, Nitz Ulrike, Park-Simon Tjoung-Won, Reimer Toralf, Rhiem Kerstin, Rody Achim, Schmidt Marcus, Schneeweiss Andreas, Schütz Florian, Sinn Hans-Peter, Solbach Christine, Solomayer Erich-Franz, Stickeler Elmar, Thomssen Christoph, Untch Michael, Witzel Isabell, Wöckel Achim, Müller Volkmar, Janni Wolfgang, Ditsch Nina
机构信息
Klinik für Gynäkologie und Gynäkologische Onkologie, Agaplesion Markus Krankenhaus, Frankfurt, Germany.
Klinik für Frauenheilkunde und Geburtshilfe, Helios Klinikum Krefeld, Krefeld, Germany.
出版信息
Breast Care (Basel). 2021 Jun;16(3):228-235. doi: 10.1159/000516420. Epub 2021 May 27.
Abstract
摘要
相似文献
1
AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2021.AGO关于局部晚期和转移性乳腺癌患者诊断与治疗的建议：2021年更新版
Breast Care (Basel). 2021 Jun;16(3):228-235. doi: 10.1159/000516420. Epub 2021 May 27.
2
AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2023.AGO关于局部晚期和转移性乳腺癌患者诊断与治疗的建议：2023年更新版
Breast Care (Basel). 2023 Aug;18(4):306-315. doi: 10.1159/000531579. Epub 2023 Jun 16.
3
AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2022.AGO关于局部晚期和转移性乳腺癌患者诊断与治疗的建议：2022年更新版
Breast Care (Basel). 2022 Aug;17(4):421-429. doi: 10.1159/000524789. Epub 2022 May 2.
4
AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2019.AGO关于局部晚期和转移性乳腺癌患者诊断与治疗的建议：2019年更新版
Breast Care (Basel). 2019 Aug;14(4):247-255. doi: 10.1159/000500999. Epub 2019 Jul 30.
5
Arbeitsgemeinschaft Gynäkologische Onkologie Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2024.妇科肿瘤学工作组：局部晚期和转移性乳腺癌患者的诊断和治疗建议：2024年更新
Breast Care (Basel). 2024 Jun;19(3):183-191. doi: 10.1159/000538753. Epub 2024 Apr 10.
6
AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2020.AGO关于局部晚期和转移性乳腺癌患者诊断与治疗的建议：2020年更新版
Breast Care (Basel). 2020 Jun;15(3):294-309. doi: 10.1159/000508736. Epub 2020 Jun 10.
7
AGO Recommendations for the Diagnosis and Treatment of Patients with Advanced and Metastatic Breast Cancer: Update 2018.AGO晚期和转移性乳腺癌患者诊断与治疗建议：2018年更新版
Breast Care (Basel). 2018 Jul;13(3):209-215. doi: 10.1159/000489331. Epub 2018 May 22.
8
AGO Recommendations for the Diagnosis and Treatment of Patients with Advanced and Metastatic Breast Cancer: Update 2017.AGO关于晚期和转移性乳腺癌患者诊断与治疗的建议：2017年更新版
Breast Care (Basel). 2017 Jul;12(3):184-191. doi: 10.1159/000477576. Epub 2017 Jun 26.
9
AGO Recommendations for the Diagnosis and Treatment of Patients with Advanced and Metastatic Breast Cancer: Update 2016.AGO晚期和转移性乳腺癌患者诊断与治疗建议：2016年更新版
Breast Care (Basel). 2016 Jun;11(3):216-22. doi: 10.1159/000447030. Epub 2016 Jun 15.
10
AGO Recommendations for the Diagnosis and Treatment of Patients with Advanced and Metastatic Breast Cancer: Update 2015.AGO关于晚期和转移性乳腺癌患者诊断与治疗的建议：2015年更新版
Breast Care (Basel). 2015 Jul;10(3):199-205. doi: 10.1159/000431248. Epub 2015 Jun 18.
引用本文的文献
1
Impact of risk and lifestyle factors on therapy goals in the treatment of breast cancer and gynecological cancer patients with integrative medicine.风险和生活方式因素对采用整合医学治疗乳腺癌和妇科癌症患者的治疗目标的影响。
Arch Gynecol Obstet. 2025 Jun;311(6):1683-1695. doi: 10.1007/s00404-025-08002-w. Epub 2025 Apr 9.
2
Narrative review of current status and recommendations in treatment for advanced triple-negative breast cancer.晚期三阴性乳腺癌治疗现状及建议的叙述性综述
Transl Breast Cancer Res. 2022 Apr 30;3:17. doi: 10.21037/tbcr-22-12. eCollection 2022.
3
Prediction of clinical response to neoadjuvant therapy in advanced breast cancer by baseline B-mode ultrasound, shear-wave elastography, and pathological information.通过基线B型超声、剪切波弹性成像和病理信息预测晚期乳腺癌新辅助治疗的临床反应
Front Oncol. 2023 May 9;13:1096571. doi: 10.3389/fonc.2023.1096571. eCollection 2023.
4
CDK4/6 Inhibitors in Advanced HR+/HER2 - Breast Cancer: A Multicenter Real-World Data Analysis.CDK4/6抑制剂在晚期激素受体阳性/人表皮生长因子受体2阴性乳腺癌中的应用：一项多中心真实世界数据分析
Breast Care (Basel). 2023 Feb;18(1):31-41. doi: 10.1159/000527917. Epub 2022 Dec 6.
5
A multicentre, randomised, double-blind, phase II study to evaluate the tolerability of an induction dose escalation of everolimus in patients with metastatic breast cancer (DESIREE).一项多中心、随机、双盲、二期研究，旨在评估依维莫司诱导剂量递增在转移性乳腺癌患者中的耐受性（DESIREE）。
ESMO Open. 2022 Dec;7(6):100601. doi: 10.1016/j.esmoop.2022.100601. Epub 2022 Nov 7.
6
Implementation of CDK4/6 Inhibitors and its Influence on the Treatment Landscape of Advanced Breast Cancer Patients - Data from the Real-World Registry PRAEGNANT.CDK4/6抑制剂的应用及其对晚期乳腺癌患者治疗格局的影响——来自真实世界登记研究PRAEGNANT的数据。
Geburtshilfe Frauenheilkd. 2022 Jul 12;82(10):1055-1067. doi: 10.1055/a-1880-0087. eCollection 2022 Oct.
7
Update Breast Cancer 2022 Part 4 - Advanced-Stage Breast Cancer.《2022年乳腺癌最新进展 第4部分 - 晚期乳腺癌》
Geburtshilfe Frauenheilkd. 2022 Sep 13;82(9):922-931. doi: 10.1055/a-1912-7362. eCollection 2022 Sep.
8
Final results of the global and Asia cohorts of KAMILLA, a phase IIIB safety trial of trastuzumab emtansine in patients with HER2-positive advanced breast cancer.KAMILLA 全球和亚洲队列的最终结果，这是一项曲妥珠单抗-美坦新偶联物用于治疗 HER2 阳性晚期乳腺癌的 IIIB 期安全性试验。
ESMO Open. 2022 Oct;7(5):100561. doi: 10.1016/j.esmoop.2022.100561. Epub 2022 Sep 7.
9
[Management of immune-related adverse events (irAEs) - what needs to be respected?].[免疫相关不良事件（irAEs）的管理——需要注意什么？]
Gynakologe. 2022;55(5):344-350. doi: 10.1007/s00129-022-04941-6. Epub 2022 Apr 26.
10
ABC6 Consensus: Assessment by a Group of German Experts.ABC6共识：德国专家小组评估
Breast Care (Basel). 2022 Feb;17(1):90-100. doi: 10.1159/000522068. Epub 2022 Jan 20.
本文引用的文献
1
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer.IMpassion131 研究是一项双盲、安慰剂对照、随机 III 期临床试验，旨在评估一线紫杉醇联合或不联合阿替利珠单抗治疗不可切除局部晚期/转移性三阴性乳腺癌的主要结果。
Ann Oncol. 2021 Aug;32(8):994-1004. doi: 10.1016/j.annonc.2021.05.801. Epub 2021 Jul 1.
2
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.帕博利珠单抗联合化疗对比安慰剂联合化疗用于治疗既往未经治疗的局部晚期不可切除或转移性三阴性乳腺癌（KEYNOTE-355）：一项随机、安慰剂对照、双盲、III 期临床研究。
Lancet. 2020 Dec 5;396(10265):1817-1828. doi: 10.1016/S0140-6736(20)32531-9.
3
Malignant Pleural Effusion: Diagnosis and Management.恶性胸腔积液：诊断与管理。
Can Respir J. 2020 Sep 23;2020:2950751. doi: 10.1155/2020/2950751. eCollection 2020.
4
Prevalence of medication related osteonecrosis of the jaw in patients treated with sequential antiresorptive drugs: systematic review and meta-analysis.序贯抗吸收药物治疗患者药物相关性颌骨坏死的患病率：系统评价和荟萃分析。
Support Care Cancer. 2021 May;29(5):2305-2317. doi: 10.1007/s00520-020-05882-3. Epub 2020 Nov 15.
5
TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes.TBCRC 048：奥拉帕利治疗转移性乳腺癌及同源重组相关基因变异的 II 期研究。
J Clin Oncol. 2020 Dec 20;38(36):4274-4282. doi: 10.1200/JCO.20.02151. Epub 2020 Oct 29.
6
A randomised trial of 4- versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancer.一项比较骨转移乳腺癌或去势抵抗性前列腺癌患者接受 4 周和 12 周骨靶向药物治疗的随机临床试验。
Eur J Cancer. 2021 Jan;142:132-140. doi: 10.1016/j.ejca.2020.08.019. Epub 2020 Oct 3.
7
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5).第五届欧洲中学教育阶段（ESO）-欧洲肿瘤内科学会（ESMO）晚期乳腺癌国际共识指南（ABC 5）
Ann Oncol. 2020 Dec;31(12):1623-1649. doi: 10.1016/j.annonc.2020.09.010. Epub 2020 Sep 23.
8
Oligometastatic breast cancer: where are we now and where are we headed?-a narrative review.寡转移乳腺癌：我们现在在哪里，未来在哪里？——一篇叙述性综述。
Ann Palliat Med. 2021 May;10(5):5954-5968. doi: 10.21037/apm-20-1128. Epub 2020 Sep 10.
9
Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial.奈拉替尼联合卡培他滨对比拉帕替尼联合卡培他滨治疗曲妥珠单抗治疗后进展的 HER2 阳性转移性乳腺癌：NALA Ⅲ期临床试验。
J Clin Oncol. 2020 Sep 20;38(27):3138-3149. doi: 10.1200/JCO.20.00147. Epub 2020 Jul 17.
10
Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial.曲妥珠单抗-美坦新偶联物（T-DM1）治疗人表皮生长因子受体 2 阳性转移性乳腺癌伴脑转移患者：来自 KAMILLA 研究队列 1 的探索性最终分析，一项单臂 IIIb 期临床研究。
Ann Oncol. 2020 Oct;31(10):1350-1358. doi: 10.1016/j.annonc.2020.06.020. Epub 2020 Jul 5.
Zotero 插件